In the last trading session, 1.49 million TG Therapeutics Inc (NASDAQ:TGTX) shares changed hands as the company’s beta touched 1.90. With the company’s per share price at $35.47 changed hands at $0.49 or 1.40% during last session, the market valuation stood at $5.63B. TGTX’s last price was a discount, traded about -31.04% off its 52-week high of $46.48. The share price had its 52-week low at $15.16, which suggests the last value was 57.26% up since then.
Analysts gave the TG Therapeutics Inc (TGTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.38. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TGTX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Instantly TGTX was in green as seen at the end of in last trading. With action 6.29%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 17.84%, with the 5-day performance at 6.29% in the green. However, in the 30-day time frame, TG Therapeutics Inc (NASDAQ:TGTX) is -4.06% down.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need a downside of -77.35% from its current market value. According to analyst projections, TGTX’s forecast low is 11.5 with 27.5 as the target high. To hit the forecast high, the stock’s price needs a 22.47% surge from its current level, while the stock would need to tank 67.58% for it to hit the projected low.
The 2025 estimates are for TG Therapeutics Inc earnings to increase by 493.33%, but the outlook for the next 5-year period is at 154.00% per year.
TGTX Dividends
TG Therapeutics Inc is expected to release its next quarterly earnings report in June.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8688% or 11.39 million shares worth $202.6 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 8.25 shares estimated at $292.76 million under it, the former controlled 5.20% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.73% of the shares, roughly 4.33 shares worth around $153.71 million.
